Jeudi 4 & vendredi 5 novembre 2010
Bordeaux
Nouvelles donnes
Nouveau départ
Adapted from: 1. Gathe et al. CROI 2008; 2. Eron J, et al. Lancet 2006;368:476–482;
3. Molina J-M, et al. CROI 2008, Abstract 4. Clumeck N, et al. EACS 2007, Abstract LBPS7/5
Baseline HIV RNA (copies/mL)
LPV/r 800/200 mg QD
LPV/r 800/200 mg QD FPV/r 700/100 mg BID
LPV/r 400/100 mg BID
M05-7301
(ITT)
Patients with VL < 50 copies/mL (%)
KLEAN2
(ITT-E, TLOVR)
LPV/r 400/100 mg BID
ARTEMIS4
(ITT-E, TLOVR)
LPV/r 400/100 mg BID
DRV/r 800/100 mg QD
<100 000 ≥100 000
0
10
20
30
40
50
60
70
80
90
100
78 75
77 75
n=664
0
10
20
30
40
50
60
70
80
90
100
n=235
<100 000 ≥100 000
6764 65 66
n=197n=209 n=237 n=235
Patients with VL <50 copies/mL (%)
86 79 86 79
56
71
0
10
20
30
40
50
60
70
80
90
100
<100 000 ≥100 000
n=343 n=52n=267
n=343 n=52 n=267
Patients with VL <50 copies/mL (%)
ATV/r 300/100 mg QD
CASTLE3
ITT-E, TLOVR)
LPV/r 400/100 mg BID
0
10
20
30
40
50
60
70
80
90
100
n=235
<100 000 ≥100 000
82 81 74 72
n=222n=228 n=106 n=134
Patients with VL <50 copies/mL (%)
IP boostés : réponse en fonction ARN VIH